Tag: Obesity drug

February 24, 2026 Off

Novo Nordisk triple agonist UBT251 delivers 19.7% weight loss in phase 2 trial

Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.

March 29, 2021 Off

By Author

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use…